Tags

Type your tag names separated by a space and hit enter

Formulation optimization of solid dispersion of mosapride hydrochloride.
Arch Pharm Res. 2011 Sep; 34(9):1467-75.AP

Abstract

Mosapride citrate (MSP) is a gastroprokinetic agent that acts as a selective 5-HT(4) agonist and accelerates the gastric emptying, and is used for the treatment of acid reflux, irritable bowel syndrome, and functional dyspepsia. The purpose of this study is to investigate the solid dispersion formulations of MSP with controlled release characteristic using various polymers, elucidate the release mechanism, and characterize the interaction patterns between MSP and polymers. Solid dispersions of MSP with different drug-to-polymer ratios were prepared by a solvent evaporation method and characterized in comparison with the simple physical mixtures. Eudragit RSPO, Eudragit RLPO, hydroxypropylmethylcellulose (HPMC) or Kollidon SR was used as a controlled-release polymer along with polyvinylpyrrolidone (PVP) as a carrier. Characterization of MSP solid dispersion was performed using thermal analysis (DSC), powder X-ray diffraction (XRD), Fourier transform-infrared (FT-IR) spectroscopy, where the drug was converted from the crystalline state to amorphous state in all polymeric carriers used. In vitro dissolution studies showed that the drug release has been extended up to 24 h by using Eudragit RSPO or HPMC. Moreover, the formulations containing higher polymer content ratio showed better slow-release profile. These results indicate that the solid dispersion formulation containing PVP/Eudragit RSPO or HPMC mixture could serve as a good controlled-release system for MSP.

Authors+Show Affiliations

College of Pharmacy, Sookmyung Women's University, Seoul 140-742, Korea.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21975808

Citation

Kim, Hye Jin, et al. "Formulation Optimization of Solid Dispersion of Mosapride Hydrochloride." Archives of Pharmacal Research, vol. 34, no. 9, 2011, pp. 1467-75.
Kim HJ, Lee SH, Lim EA, et al. Formulation optimization of solid dispersion of mosapride hydrochloride. Arch Pharm Res. 2011;34(9):1467-75.
Kim, H. J., Lee, S. H., Lim, E. A., & Kim, J. S. (2011). Formulation optimization of solid dispersion of mosapride hydrochloride. Archives of Pharmacal Research, 34(9), 1467-75. https://doi.org/10.1007/s12272-011-0908-3
Kim HJ, et al. Formulation Optimization of Solid Dispersion of Mosapride Hydrochloride. Arch Pharm Res. 2011;34(9):1467-75. PubMed PMID: 21975808.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Formulation optimization of solid dispersion of mosapride hydrochloride. AU - Kim,Hye Jin, AU - Lee,Su Hyun, AU - Lim,Eun Ah, AU - Kim,Jin-Seok, Y1 - 2011/10/06/ PY - 2010/08/02/received PY - 2010/10/28/accepted PY - 2010/10/04/revised PY - 2011/10/7/entrez PY - 2011/10/7/pubmed PY - 2012/8/4/medline SP - 1467 EP - 75 JF - Archives of pharmacal research JO - Arch. Pharm. Res. VL - 34 IS - 9 N2 - Mosapride citrate (MSP) is a gastroprokinetic agent that acts as a selective 5-HT(4) agonist and accelerates the gastric emptying, and is used for the treatment of acid reflux, irritable bowel syndrome, and functional dyspepsia. The purpose of this study is to investigate the solid dispersion formulations of MSP with controlled release characteristic using various polymers, elucidate the release mechanism, and characterize the interaction patterns between MSP and polymers. Solid dispersions of MSP with different drug-to-polymer ratios were prepared by a solvent evaporation method and characterized in comparison with the simple physical mixtures. Eudragit RSPO, Eudragit RLPO, hydroxypropylmethylcellulose (HPMC) or Kollidon SR was used as a controlled-release polymer along with polyvinylpyrrolidone (PVP) as a carrier. Characterization of MSP solid dispersion was performed using thermal analysis (DSC), powder X-ray diffraction (XRD), Fourier transform-infrared (FT-IR) spectroscopy, where the drug was converted from the crystalline state to amorphous state in all polymeric carriers used. In vitro dissolution studies showed that the drug release has been extended up to 24 h by using Eudragit RSPO or HPMC. Moreover, the formulations containing higher polymer content ratio showed better slow-release profile. These results indicate that the solid dispersion formulation containing PVP/Eudragit RSPO or HPMC mixture could serve as a good controlled-release system for MSP. SN - 0253-6269 UR - https://www.unboundmedicine.com/medline/citation/21975808/Formulation_optimization_of_solid_dispersion_of_mosapride_hydrochloride_ L2 - https://dx.doi.org/10.1007/s12272-011-0908-3 DB - PRIME DP - Unbound Medicine ER -